JIKEI mitigulinide vs sitagliptin study on glycemic variance using continuous glucose monitoring.

JIKEI mitigulinide vs sitagliptin study on glycemic variance using continuous glucose monitoring. - J-MISSION

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005517

Enrollment

Registered

2011-04-27

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Mitiglinide Sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type2 diabetes whose HbA1c is >6.5 and <9.0 under life style intervention + ordinal dosage of SU or metformin or alpha-glucosidase inhibitor treatment

Exclusion criteria

Exclusion criteria: type 1 diabetes diabetic ketosis infection past history of abdominal operation past history of ileus renal failure liver damage on insulin treatment past history of allergy against Sitagliptin or Mitiglinide Cancer patient Dialysis patient

Design outcomes

Primary

Measure	Time frame
glucose variability	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026